Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cellectis S.A. ADR
(NQ:
CLLS
)
2.370
+0.050 (+2.16%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
72,965
Open
2.230
Bid (Size)
2.240 (1)
Ask (Size)
2.400 (5)
Prev. Close
2.320
Today's Range
2.230 - 2.400
52wk Range
0.9628 - 3.773
Shares Outstanding
45,484,310
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
August 07, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-22.80%
-22.80%
1 Month
+15.61%
+15.61%
3 Month
-14.75%
-14.75%
6 Month
-12.87%
-12.87%
1 Year
+24.74%
+24.74%
More News
Read More
Cellectis Provides Financial Results for the Second Quarter 2024
August 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
August 01, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
June 20, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
June 04, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024
May 28, 2024
Via
InvestorPlace
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024
From
Cellectis Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
April 29, 2024
Via
InvestorPlace
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
April 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
April 10, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.